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Abstract
Meals high in SFA, particularly palmitate, are associated with postprandial inflammation and insulin resistance. Milk fat globule membrane (MFGM) has
anti-inflammatory properties that may attenuate the negative effects of SFA-rich meals. Our objective was to examine the postprandial metabolic and
inflammatory response to a high-fat meal composed of palm oil (PO) compared with PO with an added dairy fraction rich in MFGM (PO+MFGM)
in overweight and obese men and women (n 36) in a randomised, double-blinded, cross-over trial. Participants consumed two isoenergetic high-fat
meals composed of a smoothie enriched with PO with v. without a cream-derived complex milk lipid fraction ( dairy fraction rich in MFGM) separated
by a washout of 1–2 weeks. Serum cytokines, adhesion molecules, cortisol and markers of inflammation were measured at fasting, and at 1, 3 and 6 h
postprandially. Glucose, insulin and lipid profiles were analysed in plasma. Consumption of the PO+MFGM v. PO meal resulted in lower total cholesterol
(P= 0·021), LDL-cholesterol (P= 0·046), soluble intracellular adhesion molecule (P= 0·005) and insulin (P= 0·005) incremental AUC, and increased IL-
10 (P= 0·013). Individuals with high baseline C-reactive protein (CRP) concentrations (≥3 mg/l, n 17) had higher (P = 0·030) insulin at 1 h after the PO
meal than individuals with CRP concentrations <3 mg/l (n 19). The addition of MFGM attenuated this difference between CRP groups. The addition of a
dairy fraction rich in MFGM attenuated the negative effects of a high-SFA meal by reducing postprandial cholesterol, inflammatory markers and insulin
response in overweight and obese individuals, particularly in those with elevated CRP.
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The postprandial state has been highlighted as an important
transitory period when significant vascular damage can occur
and has recently been implicated in the causal processes of
CVD(1). Postprandial inflammatory and lipaemic responses
are pronounced in individuals with obesity, the metabolic syn-
drome (MetS) and type 2 diabetes(2–5), in part because the
magnitude of the postprandial inflammatory response is
correlated with insulin resistance(6,7). Current literature sug-
gests that the inflammation of the postprandial state adds to
the already pro-inflammatory environment in individuals
with obesity-induced metabolic disease, intensifying the
overall systemic inflammation that underlies metabolic dys-
function(8). Given the rise in overweight and obesity world-
wide(9), potential nutritional interventions that can limit the
Abbreviations: CRP, C-reactive protein; iAUC, incremental AUC; MetS, metabolic syndrome; MFGM, milk fat globule membrane; PO, palm oil; sICAM, soluble intracellular
adhesion molecule.
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postprandial inflammatory response would be of great public
health benefit.
The postprandial inflammatory response is influenced by
the fat content and composition of the test meal(10–13). It
has been shown that SFA induce inflammation postpran-
dially(8). Palmitic acid in particular appears to be detrimental.
The consumption of palmitic acid acutely increases the insulin
response compared with oleic acid and n-3 fatty acids(14) and
this was shown to be related to the adverse effects of palmitate
on both β-cell function and insulin sensitivity in the postpran-
dial state(15). Palmitate, either as an isolated fatty acid or as part
of a high-SFA meal, increases inflammatory markers in the
postprandial state(16). Palm oil (PO) is enriched in palmitate
and has been used widely in the food industry as a substitute
for trans-fatty acids, which are known to have deleterious
effects on CVD risk(17).
Milk fat globule membrane (MFGM) fractions have previ-
ously been reported to reduce inflammation in in vitro and ani-
mal models(18–21). MFGM, a protein–lipid complex originating
from the apical surface of mammary epithelial cells, surrounds
the fat globules in milk and is found in dairy products at vary-
ing levels. Specific proteins and lipids of MFGM are associated
with health-promoting bioactive functions. For example, one
major MFGM-associated protein, lactadherin, was reported
to bind and neutralise viruses, reduce intestinal inflammation,
improve intestinal permeability, and repair intestinal epithe-
lium(20,22–24). MFGM-derived polar lipids were reported to
have bactericidal properties, bind enterotoxigenic pathogens
and reduce intestinal inflammation(19,23,25–27). In addition to
functions attributed to its individual components, MFGM as
a complex also reduced inflammation in vitro, in animals and
clinically(18,21,28). However, it is not known whether the add-
ition of a dairy fraction rich in MFGM to meals high in satu-
rated fat would blunt the postprandial inflammatory response
in human subjects.
The objective of this study was to determine the postpran-
dial inflammatory effect of a high-saturated fat meal using PO
with and without the addition of MFGM in overweight and
obese adults. We hypothesised that consuming a high-fat
PO +MFGM meal would result in lower pro-inflammatory
serum markers compared with the isoenergetic PO meal.
Materials and methods
Participants
A total of seventeen adult men and nineteen adult women
(total of thirty-six participants) were recruited from the
Davis and greater Sacramento areas of California to participate
in this study. To qualify, individuals had to be between 18 and
65 years of age, and either be overweight according to their
BMI (25–29·9 kg/m2) plus have two or more MetS traits
according to the definition of the American Heart
Association or simply be obese according to their BMI (30–
39·9 kg/m2) and have any number of MetS traits. The MetS
is defined by having three or more of the following traits:
waist circumference >40 inches (>102 cm) for men and 35
inches (>89 cm) inches for women; fasting plasma TAG ≥
150 mg/dl (≥ 1·70 mmol/l); fasting plasma HDL-cholesterol
<40 mg/dl (<1·04 mmol/l) for men and <50 mg/dl (<1·30
mmol/l) for women; blood pressure ≥130/85 mmHg; and
fasting glucose ≥100 mg/dl (≥5·56 mmol/l)(29). Individuals
were excluded from participation for the following reasons:
diagnosis of immune-related diseases, gastrointestinal disor-
ders, cancer, type 2 diabetes, eating disorder, allergies to the
provided study foods, poor vein accessibility according to
the research phlebotomist, or a body-weight change greater
than 10 % over the past 6 months. Individuals were excluded
from participation if they used the following: weight loss med-
ications; daily non-steroidal anti-inflammatory drugs (NSAID);
anti-inflammatory supplements; corticoid steroids; tobacco;
change in hormonal birth control regimen with the past 6
months; initiation of statins in past 3 months. Because of pos-
sible confounding effects on inflammatory outcomes, dietary
exclusion criteria were as follows: >1 serving of fish/week;
>14 g fibre/1000 kcal (4184 kJ) per d; <16:1 of total dietary
n-6:n-3 ratio; >1 % of daily energy as trans-fats; and a vegetar-
ian diet pattern. If individuals had initiated an exercise pro-
gramme within the past 6 months, planned to become
pregnant within the next 6 months, or were already pregnant
or lactating, they were not enrolled in the study. To determine
enrolment eligibility, questionnaires were administered regard-
ing health history, diet and medication. An online FFQ was
used to assess dietary intake and a fasting blood sample was
drawn for the analysis of blood lipids and glucose.
Additional anthropometric measurements were taken during
the screening visit to determine MetS traits (weight, height,
and waist circumference).
This study was approved from an ethical standpoint by the
Institutional Review Board of the University of California,
Davis. Informed consent was given in writing by all study par-
ticipants prior to starting the study protocol. The study was
registered at clinicaltrials.gov under NCT01811329.
Study design
Two isoenergetic test meals were consumed by the participants
in a randomised, double-blinded, two-way cross-over design.
A high-fat PO meal was compared against a high-fat
PO meal with the addition of MFGM (PO+MFGM).
Participants were assigned to test meal order using a random
number generator which randomly returned either a 0 or 1,
with a 0 being assigned to PO first followed by PO +
MFGM second, and a 1 being assigned to PO +MFGM
first followed by PO second. Test meals were consumed in
random order on different test days separated by a washout
phase of minimally 1 week and maximally 2 weeks to avoid
any carry-over effects. After each washout, participants con-
sumed the alternate test meal.
To limit confounding effects, the consumption of anti-
inflammatory supplements, alcohol or NSAID was not per-
mitted for 72 h before each test day. At 24 h prior to the
test day, vigorous exercise was prohibited to avoid increasing
inflammatory markers and conversely consumption of seafood
was not allowed to avoid a suppression of inflammatory mar-
kers. To ensure compliance, participants filled out a 1-d food
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record for the 24 h prior to each test day. The dietary records
were analysed using the Nutrition Data System for Research
(NDSR; University of Minnesota).
Participants arrived at the Western Human Nutrition
Research Center after a 10–12 h fast on each test day. The
24 h diet record was collected and participants were asked
to complete a modified gastrointestinal questionnaire(30). A
fasted blood sample was drawn via venepuncture. Blood pres-
sure, heart rate, weight and waist circumference were mea-
sured. The dietary test meal was then consumed completely
within 20 min. Postprandial blood draws were conducted at
1, 3 and 6 h. These time points were determined based on pre-
vious postprandial clinical trials observing a peak in pro-
inflammatory cytokine concentrations around 3–6 h after
consuming a high-fat meal(6,31).
Consumption of any food other than the test meal was not
permitted, but bottled water was offered throughout the test
day. Participants were offered the option to stay at the research
facility or leave between blood draws via car to limit physical
activity and had to return 15 min before their scheduled
blood draw to allow for a 10 min rest period prior to each
blood draw.
Dietary challenges
The two test meals were made up of a bagel with strawberry
preserves along with either a PO or PO +MFGM smoothie.
In each instance the smoothie consisted of deionised water,
cream of tartar, PO shortening, and raspberry sorbet.
Additionally, the PO +MFGM smoothie contained BPC50,
a cream-derived complex milk lipid fraction powder (β
serum concentrate) that is a proprietary product supplied by
Fonterra Co-operative Group Ltd (New Zealand)(32). BPC50
is comprised of the following (% w/w): 52 % protein of
which 13·2 % is membrane-derived protein, 6·6 % lactose
and 36·2 % total fat (22·5 % TAG and 13·7 % phospholipids),
0·63 % gangliosides (GD3), and 5·2 % ash(33–35). The six
highest abundant MFGM-derived proteins reported in
BPC50 include: fatty acid-binding protein, butyrophilin, lactad-
herin, adipophilin, xanthine oxidase and mucin(35). The PO
smoothie contained whey protein isolate to match the protein
content found in the BPC50 product. For ingredient details,
see Supplementary Table S1. Participants were instructed to
eat the entire meal, rinse their cup with water, and drink the
rinse-water.
Each test meal provided 40 % of the participant’s total daily
energy intake. Energy intake was determined by using the
National Academy of Sciences equation from the Institute of
Medicine Dietary Reference Intake(36). To determine each par-
ticipant’s physical activity level the Baecke Physical Activity
questionnaire was used(37).
The two isoenergetic test meals were constructed to vary
less than 0·2 % in macronutrients and provided about 55 %
fat, about 30 % carbohydrates, and about 15 % protein.
Each test meal provided between 49 and 87 g of fat depending
on each individual’s energy intake, 61–107 g of carbohydrates,
and 31–55 g of protein (Table 1). Test meal nutrient compos-
ition was estimated using NDSR (University of Minnesota).
The addition of MFGM (ranging from 53·2 to 93·1 g depend-
ing on each individual’s energy intake) replaced 31 % of the fat
of each participant’s meal (34 % of the total energy).
Blood analyses
Whole blood was drawn at baseline, and at 1, 3 and 6 h after
the meal. Serum tubes were allowed to clot at room tempera-
ture for 30 min, and then centrifuged at 1300 g at 4°C for 10
min. EDTA-whole blood tubes were kept on ice during and
after blood collection and were centrifuged within 30 min of
collection at 1300 g at 4°C for 10 min. After centrifugation,
the serum and plasma tubes were kept on ice during aliquot-
ing. Subsequently, plasma and serum aliquots were directly
frozen at –70°C until analysed.
Inflammatory markers
Serum samples from all four time points were analysed for
cytokine concentrations (IL-10, IL-1β, IL-2, IL-4, IL-6, IL-8,
Table 1. Nutrient composition of test meals†
(Mean values and standard deviations)
PO meal
PO +MFGM
meal
Mean SD Mean SD
Energy (kcal) 1088·1 189·3 1088·1 189·2
Energy (kJ) 4552·4 791·8 4552·7 791·7
Total carbohydrate
g 82·7 14·4 83·2 14·5
% total energy 30·4 0·0 30·6 0·0
Total protein
g 42·5 7·4 43 7·5
% total energy 15·6 0·0 15·8 0·0
Total fat
g 67·3 11·7 67·5 11·7
% total energy 55·6 0·0 55·8 0·0
Total SFA
g 32·6 5·7 34·6 6·0
% total energy 27·0 0·0 28·6 0·0
Total MUFA
g 24·6 4·3 22·7 3·9
% total energy 20·3 0·0 18·8 0·0
Total PUFA*
g 6·9 1·2 6·1 1·1
% total energy 5·7 0·0 5·1 0·0
SFA 4 : 0 (butyric acid) (%) 0 0 0·2 0·0
SFA 6 : 0 (caproic acid) (%) 0 0 0·2 0·0
SFA 8 : 0 (caprylic acid) (%) 0 0 0·2 0·0
SFA 10 : 0 (capric acid) (%)* 0 0 0·5 0·1
SFA 12 : 0 (lauric acid) (%)* 0·1 0·0 0·8 0·1
SFA 14 : 0 (myristic acid) (%)* 0·7 0·1 2·5 0·4
SFA 16 : 0 (palmitic acid) (%)* 28·7 5 24·8 4·3
SFA 18 : 0 (stearic acid) (%)* 2·9 0·5 4·7 0·8
MUFA 16 : 1 (palmitoleic acid) (%)* 0·2 0·0 0·5 0·1
MUFA 18 : 1 (oleic acid) (%)* 24·3 4·2 22·2 3·9
PUFA 18 : 2 (linoleic acid) (%) 6·6 1·1 5·1 0·9
PUFA 18 : 3 (linolenic acid) (%) 0·3 0·1 0·5 0·1
PO, palm oil; PO +MFGM, palm oil + milk fat globule membrane.
* Significant difference between the two meals (P < 0·05).
†Comparison of the dietary challenges. Nutrient composition obtained using the
Nutrition Data System for Research (NDSR). Test meals were based on each indivi-
dual’s total energy expenditure; thus values shown are average of all test meals (n
36).
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TNFα, monocyte chemotactic protein-1), as well as the vascu-
lar injury molecules C-reactive protein (CRP), serum amyloid
A, soluble intracellular adhesion molecule (sICAM) and sol-
uble vascular adhesion molecule. Plasma was used to measure
IL-18 concentrations. A commercially available Multi Spot
ELISA kit was used to quantify the concentrations of these
markers (SECTOR Imager 2400; Meso Scale Discovery).
The protocol was followed as recommended by the manufac-
turer. Briefly, pre-coated plates with capture antibodies were
incubated with 25–50 µl of serum or plasma. After washing
the plates a labelled detection antibody was added. Upon elec-
trochemical stimulation the bound detection antibodies emit
light, which is measured by the plate reader to quantify the
amount of each protein of interest.
Cortisol
Serum cortisol was measured at all times points using the
DetectX Cortisol Enzyme Immunoassay kit (Arbor Assays).
Briefly, a cortisol–peroxidase conjugate and a monoclonal cor-
tisol antibody were added to a pre-coated ninety-six-well plate.
Upon incubation, serum samples were added to each well and
allowed to bind with the cortisol–peroxidase conjugate. The
total amount of cortisol present in each sample was then cal-
culated based on the absorbance detected by the reader.
Metabolic parameters
At each time point plasma glucose, insulin, and a lipid panel
including TAG, total cholesterol, HDL-cholesterol,
LDL-cholesterol, HDL:LDL ratio, and non-HDL-cholesterol
were assessed by standard clinical techniques in the clinical
laboratory of University of California Medical Center
(Sacramento, CA).
Clinical characteristics
Body weight, height, waist circumference, blood pressure and
heart rate were measured on each test day. Body weight was
measured with a calibrated scale (6002 Wheelchair Scale;
Scale-tronix). Waist circumference was measured in the stand-
ing position with measurements midway between the lateral
lower rib margin and the ileac crest (QM2000 Measure
Mate; QuickMedical). Height was measured with a wall-
mounted stadiometer (Ayrton Stadiometer Model S100;
Ayrton Corporation). Blood pressure and resting heart rate
were taken in the upright seated position using the appropri-
ately sized cuff (Carescape V100 with Critikon Dura-cuf for
either adults or large adults; GE Medical Instruments). Total
fat mass and lean mass were assessed using dual-energy
X-ray absorptiometry (Lunar Prodigy instrument; GE
Medical Instruments).
Statistical analysis
The sample size was calculated based on the primary outcome
marker IL-6 using the means and standard deviations from a
similar human study with overweight men at risk for
developing the MetS(31). To ensure 95 % confidence of the
results and 80 % power the sample size calculation indicated
that thirty-six participants would be needed.
Statistical analyses were conducted on SPSS version 20.0
software for Macintosh (SPSS). Differences were considered
significant at P< 0·05. Normality was established visually
and numerically using histograms, Q–Q plots and the
Shapiro–Wilk test. Data were transformed as needed. When
concentrations for markers were below the lower limit of
detection (LLOD) (IL-10; 23 % and IL-6; 9 %) for <25 %
of the samples, the value was calculated as the LLOD divided
by 10. When concentrations for markers were below the
LLOD for >25 % of the samples, the data were excluded
from statistical analyses (IL-1β and IL-4). Cases with values
more than three box lengths from the 75th percentile or
25th percentile were deemed outliers and removed from all
analyses; this only applied to sICAM where two subjects
were excluded.
To determine if dietary differences existed between test meal
composition and baseline analyte concentrations a paired t test
was used. A mixed linear model was performed with treatment
and time as fixed factors, participants as the random effect and
treatment × time as the interaction term. If time was signifi-
cant, multiple-comparison post hoc analysis with Bonferroni
correction was carried out to compare the concentrations at
0–1 h, 0–3 h, 0–6 h, 1–3 h, 1–6 h, and 3–6 h.
The incremental AUC (iAUC, area above baseline) and
decremental (area below baseline) using the conventional trap-
ezoid method were used to compare postprandial responses
between test meals(38). The iAUC was chosen over the total
AUC because it reflects the postprandial rise of these metab-
olite concentrations above the non-zero fasting value(39). iAUC
between test meals were compared by one-way ANOVA.
To determine if pre-existing clinical conditions affected the
inflammatory responses to the test meals, secondary analyses
were conducted. Participants were coded as having high or
low CRP levels based on their baseline levels prior to receiving
either test meal treatment. High CRP was defined as a concen-
tration ≥3 mg/l (n 17), low CRP was defined as <3 mg/l (n
19)(40). Baseline characteristics of each CRP group can be
found in Table 2. ANCOVA was used to identify statistically
significant differences in postprandial inflammatory markers
between test meals using CRP as the covariate variable.
Results
Participant characteristics
After screening 207 participants, thirty-eight were enrolled to
start the study (Fig. 1). Thirty-six participants completed
both postprandial test days. The two participants who did
not finish the trial were disqualified due to scheduling difficul-
ties and the initiation of medication that could confound the
results. Each participant was randomly assigned to one test
meal and after a 1- to 2-week washout period, they were
crossed-over to the alternate test meal. The majority of the
study population was Caucasian (67 %) or Hispanic (28 %).
Out of the total thirty-six participants, six were overweight
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with two MetS traits, three were overweight with three or more
MetS traits, twenty-one were obese with zero to two MetS
traits, and six were obese with three MetS traits. The baseline
characteristics of the participants are shown in Table 2.
Dietary challenge
Participants consumed two test meals, a high-fat PO test meal
and a high-fat PO +MFGM test meal. The meals (Table 1)
were isoenergetic and comparable for macronutrient compos-
ition, not varying by more than 0·2% for carbohydrates, pro-
tein or fat. The total weight of SFA and MUFA did not differ
between the PO v. PO +MFGM test meals. However, the PO
meal contained a significantly higher total amount of PUFA
compared with the PO +MFGM test meal. The relative abun-
dance of 18 : 2n-6 was not significantly different between the
two test meals; however, since 18 : 2n-6 is the predominant
PUFA in the two meals, and since the PO meal had higher
total PUFA, the PO meal had a higher total amount of 18 :
2n-6. The relative abundances of specific SFA and MUFA
were significantly different: the PO +MFGM meal had more
10 : 0, 12 : 0, 14 : 0, 18 : 0 and 18 : 1n-9 whereas the PO
meal had more 16 : 0 and 16 : 1n-7. These differences in rela-
tive abundances of fatty acids are reflective of the composition
of PO, which is enriched in palmitate (16 : 0), and MFGM,
which is enriched in medium-chain SFA characteristic of
dairy fat.
Metabolic parameters
There was a time × treatment interaction for total cholesterol
(P = 0·04), HDL-cholesterol (P = 0·01), TAG (P< 0·0005),
non-HDL-cholesterol (P= 0·04) and insulin (P < 0·0005)
(Table 3). Among these lipid makers, the greater change in
total cholesterol was observed in response to the PO test
meal; there was a 5 % increase from 0 to 1 h as well as
from 0 to 6 h. HDL-cholesterol increased from 0 to 1 h by
4 % and decreased from 1 to 3 h by 4 % in response to the
Table 2. Participant baseline characteristics*
(Mean values and standard deviations)
All participants Low CRP‡ High CRP‡
Mean SD MetS criteria† Mean SD Mean SD
Age (years) 42·9 14·0 42·4 13·6 43·6 14·9
Weight (kg) 92·9 12·2 93·5 11·9 92·2 12·8
Height (m) 1·7 0·1 1·7 0·1 1·7 0·1
BMI (kg/m2) 31·7 2·6 31·9 2·6 31·5 2·5
Total body fat (%) 36·7 7·8 34·2 8·3 39·5 6·3
Total body fat, male (%)§ 31·0 6·2 28·5 4·3 35·5 6·8
Total body fat, female (%)§ 41·9 4·9 42·1 5·1 41·7 5·0
Android fat (g) 3262·9 799·9 40·5 6·7 46·1 4·2
Android fat, male (g) 3370·8 934·1 37·2 5·7 45·2 3·3
Android fat, female (g) 3166·3 669·0 45·0 5·3 46·7 4·7
Gynoid fat (g) 5353·3 1452·0 36·9 8·6 39·5 7·0
Gynoid fat, male (g) 4829·2 1325·8 31·2 5·0 33·5 5·3
Gynoid fat, female (g) 5822·1 1430·2 44·8 5·7 42·7 5·6
WC (inches) 39·3 3·2 38·8 2·9 39·9 3·4
WC, male (inches) 41·1 3·1 >40 40·2 2·9 42·8 2·9
WC, female (inches) 37·7 2·2 >35 36·9 1·6 38·2 2·4
WC (cm) 99·8 8·1 98·6 7·4 101·3 8·6
WC, male (cm) 104·4 7·9 >102 102·1 7·4 108·7 7·4
WC, female (cm) 95·8 5·6 >89 93·7 4·1 97·0 6·1
Systolic BP (mmHg) 123·9 13·6 ≥130 123·1 9·5 124·8 17·4
Diastolic BP (mmHg) 75·0 10·3 ≥85 76·0 9·2 73·9 11·6
HDL-cholesterol
mg/dl 48·3 14·1 48·4 14·2 48·2 14·4
mmol/l 1·25 0·37 1·25 0·37 1·25 0·37
HDL-cholesterol, male
mg/dl 43·2 11·7 <40 42·5 13·7 44·5 7·8
mmol/l 1·12 0·30 <1·04 1·10 0·35 1·15 0·20
HDL-cholesterol, female
mg/dl 52·9 14·7 <50 56·5 10·9 50·3 16·9
mmol/l 1·37 0·38 <1·30 1·46 0·28 1·30 0·44
Fasting glucose
mg/dl 91·0 7·4 ≥100 92·0 7·8 89·9 7·1
mmol/l 5·06 0·41 ≥5·56 5·11 0·43 4·99 0·39
Fasting TAG
mg/dl 122·5 57·8 ≥150 106·0 41·1 140·9 68·7
mmol/l 1·38 0·65 ≥1·70 1·20 0·46 1·59 0·78
MetS, metabolic syndrome; CRP, C-reactive protein; WC, waist circumference; BP, blood pressure.
* Measurements taken at screening visit (n 36).
†MetS as defined by the American Heart Association.
‡ Low baseline CRP n 19; high baseline CRP n 17.
§ Male n 17, female n 19.
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PO test meal. In response to the PO +MFGM test meal,
TAG concentration increased by 104 % from 0 to 3 h and
non-HDL-cholesterol concentration increased by 22 % from
0 to 1 h.
The total concentration of each analyte over the 6 h post-
prandial time was calculated as the iAUC and compared
between test meals. The addition of MFGM to the test meal
resulted in significantly lower concentrations of total choles-
terol (P = 0·02 with all subjects included, P = 0·04 with two
outliers removed), LDL-cholesterol (P= 0·046) and a signifi-
cantly higher concentration of TAG (P = 0·025) when com-
pared with the PO meal alone (Supplementary Fig. S1).
When total insulin concentration was compared over the 6 h
postprandial period (i.e. the iAUC of insulin from 0 to 6 h) the
addition of MFGM resulted in a significantly lower exposure
to insulin (P = 0·005) (Fig. 2). Neither insulin nor glucose con-
centrations at baseline differed between the two test meals.
There were no effects of treatment on insulin and glucose con-
centrations in the postprandial period; however, there was a
rapid increase in insulin concentration from 0 to 1 h (P<
0·0005) that was complemented by a decrease in glucose (P
< 0·0005). From 1 to 3 h there was an increase back to base-
line levels for glucose (P = 0·003) and a corresponding
decrease in insulin concentrations (P < 0·0005) although
still greater than the 0 h value (P< 0·0005). The increase in
insulin concentration was dampened from 0 to 1 h by more
than 50 % when MFGM was added to the test meal, resulting
in a 482 % increase v. a 234 % increase for PO v. PO +
MFGM, respectively (time × treatment effect, P < 0·0005).
To examine if there was a difference between participants
who had high v. low baseline CRP concentrations, additional
secondary analyses were conducted. Participants with baseline
CRP concentration ≥3 mg/l (coded as ‘high’) had significantly
higher insulin concentrations at 1 h after consuming the PO
meal (P = 0·03). The addition of MFGM to the meal sup-
pressed the insulin response in the high CRP group, thus
removing any significant difference between the high and
low CRP groups (Fig. 3).
Inflammatory markers
The two cytokines IL-1β and IL-4 fell below the detection
limit for 70 and 95 % of samples, respectively. Consequently,
these markers were not included in the statistical analyses
reported here. Similar results for IL-1β and IL-4 have been
observed in previous studies(41,42).
Fig. 1. Enrolment and follow-up of participants in the randomised cross-over trial. PO, palm oil; PO +MFGM, palm oil + milk fat globule membrane.
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Baseline concentrations of all markers related to inflamma-
tion were comparable between the two treatments. When ana-
lysed as iAUC, IL-10 was significantly higher (P= 0·013) and
sICAM was significantly lower in response to the PO +
MFGM test meal (P = 0·005 for all) (Fig. 4). An interaction
effect between time and treatment was observed for IL-10
(P = 0·03), IL-8 (P = 0·04) and sICAM (P = 0·02) (Table 4).
Over time IL-10 gradually, but not significantly, declined on
the PO treatment whereas on the PO +MFGM treatment
IL-10 increased. There was a significant decrease in IL-8
from 0–3 h and 1–3 h and a significant increase in concentra-
tion from the 3–6 h time points (P < 0·05 for all) following the
PO meal, but IL-8 was unchanged after the PO +MFGM
meal. Concentrations for sICAM significantly increased from
0–1 h, 0–6 h, and 3–6 h and significantly decreased between
the 1–3 h time points (P< 0·05 for all) after consumption of
the PO meal and, like IL-8, was unchanged after the PO +
MFGM challenge. There was no treatment effect observed
for any of the other inflammatory markers, but a significant
change over time was observed for IL-6, IL-8, TNFα, CRP,
Table 3. Concentrations of metabolic markers with significant interaction effects
(Mean values and standard deviations)
Time point
0 h 1 h 3 h 6 h
Mean SD Mean SD Mean SD Mean SD Time × treatment: P
Total cholesterol (mg/dl) 0·04
PO meal 194·9 38·5 204·2* 40·8 201·4* 39·9 203·9* 39·6
PO +MFGM meal 198·7 37·6 199·7 37·6 207·1 37·4 203·7 35·8
Total cholesterol (mmol/l) 0·04
PO meal 5·05 1·00 5·29* 1·06 5·22* 1·03 5·28* 1·03
PO +MFGM meal 5·15 0·97 5·17 0·97 5·36 0·97 5·28 0·93
HDL-cholesterol (mg/dl) 0·01
PO meal 49·6 14·5 51·6* 15·3 49·3† 15·3 49·9† 15·3
PO +MFGM meal 50·2 14·0 50·6 14·5 50·4 14·5 49·7 14·4
HDL-cholesterol (mmol/l) 0·01
PO meal 1·28 0·37 1·34* 0·40 1·28† 0·40 1·29† 0·40
PO +MFGM meal 1·30 0·36 1·31 0·38 1·30 0·37 1·29 0·37
TAG (mg/dl) <0·0005
PO meal 126·6 56·5 182·9* 77·9 223·9*† 114·4 209·6*‡ 82·9
PO +MFGM meal 130·1 70·6 174·9 58·2 265·1 119·8 210·4 111·8
TAG (mmol/l) <0·0005
PO meal 1·43 0·64 2·07* 0·88 2·53*† 1·29 2·37*‡ 0·94
PO +MFGM meal 1·47 0·80 1·98 0·66 3·00 1·35 2·38 1·26
Non-HDL-cholesterol (mg/dl) 0·04
PO meal 145·4 35·3 152·6* 36·5 152·2* 36·3 154·0* 37·2
PO +MFGM meal 148·5 34·9 180·5 166·6 157·0 34·5 154·0 33·8
Non-HDL-cholesterol (mmol/l) 0·04
PO meal 3·77 0·91 3·95* 0·95 3·94* 0·94 3·99* 0·96
PO +MFGM meal 3·85 0·90 4·67 4·32 4·07 0·89 3·99 0·88
Insulin (μIU/ml) <0·0005
PO meal 14·0 6·1 81·7* 69·3 34·4*† 28·6 Not measured
PO +MFGM meal 16·4 10·6 54·8 46·1 39·6 25·9 Not measured
Insulin (pmol/l) <0·0005
PO meal 100·7 44·1 586·4* 497·4 246·5*† 205·5 Not measured
PO +MFGM meal 117·5 75·9 392·9 330·4 283·8 186·0 Not measured
PO, palm oil; PO +MFGM, palm oil + milk fat globule membrane.
* Significantly different from 0 h when both treatments analysed together (P < 0·05).
†Significantly different from 1 h when both treatments analysed together (P < 0·05).
‡Significantly different from 3 h when both treatments analysed together (P < 0·05).
Fig. 2. Postprandial serum insulin concentrations. Serum insulin concentra-
tions over the 6 h postprandial period after a high-fat mixed meal containing
palm oil (PO) v. palm oil + milk fat globule membrane (PO +MFGM). Data
are incremental AUC (iAUC). Values are means, with standard deviations
represented by vertical bars. * The addition of MFGM resulted in a significant
decrease of insulin concentration (P = 0·005).
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serum amyloid A, sICAM, soluble vascular adhesion molecule
and cortisol (P< 0·05 for all) (Table 4). There was no time or
treatment effect for monocyte chemotactic protein-1.
Secondary analysis using baseline CRP as a covariate
revealed a statistically significant difference for IL-6 at each
time point (P< 0·05 for each time point) between participants
with high v. low baseline CRP concentrations after consuming
the PO test meal. After consuming the PO+MFGM test
meal, this difference was no longer significant, suggesting
that MFGM may attenuate the postprandial inflammatory
response in individuals with high CRP levels.
Cortisol
Analysis of serum cortisol revealed no time × treatment inter-
action effect or a treatment effect. There was a significant
decrease in cortisol concentration for all time points (P <
0·05 for all time points) over the course of each test day.
Decreases throughout the day, from baseline to 1 h, 1–3 h,
and 3–6 h were as follows: 15, 33 and 43 %, respectively.
This observed decrease throughout the day is consistent
with diurnal patterns of cortisol.
Discussion
This study was designed to determine if the addition of
MFGM to a high-fat meal containing plant-based saturated
fat influences postprandial inflammation in overweight and
obese individuals. Our results showed that adding a dairy frac-
tion rich in MFGM to a high-fat meal may lower CVD risk by
reducing postprandial insulin, total cholesterol and
LDL-cholesterol as well as sICAM concentrations while
increasing the concentration of anti-inflammatory IL-10.
Compared with PO, consumption of the PO +MFGM test
meal resulted in a significantly higher concentration of IL-10 at
6 h postprandial. IL-10 is an anti-inflammatory cytokine which
has been recognised for its atheroprotective effects(43). Our
results suggest that the addition of MFGM to a high-SFA
meal improves postprandial inflammation in an overweight
and obese population already in a chronically inflamed state.
To our knowledge we are the first to examine the postprandial
effect on IL-10 after a high-fat dietary challenge with and with-
out MFGM in human subjects.
Cellular adhesion molecules, such as sICAM, are key players
in the early events of atherosclerosis development(44). The
consumption of the PO+MFGM test meal resulted in a sig-
nificantly lower concentration of sICAM over the postprandial
period when compared with PO alone. In large prospective
studies of both healthy individuals and patients with CVD,
concentrations of sICAM were positively associated with
future incidents of CVD(45–47). In our study the total amount
of sICAM over the 6 h postprandial period in response to PO
+MFGM was significantly lower by 95 % compared with PO.
These results suggest that the addition of a dairy fraction rich
Fig. 3. Insulin concentrations in high (––) v. low (––) baseline C-reactive pro-
tein (CRP) groups. (a) There was a significant difference between the high and
low baseline CRP groups at the 1 h time point (P = 0·03) after consuming the
palm oil meal. (b) When the palm oil + milk fat globule membrane meal was
consumed there was no difference between the high and low baseline CRP
groups for insulin. Values are means, with standard deviations represented
by vertical bars. To convert insulin to pmol/l, multiply by 6·945.
Fig. 4. Postprandial serum concentrations of IL-10 (a) and soluble intracellular adhesion molecule (sICAM) (b). Serum IL-10 and sICAM concentrations over the 6 h
postprandial period after a high-fat mixed meal containing palm oil (PO) v. palm oil + milk fat globule membrane (PO +MFGM). Data are incremental AUC (iAUC).
Values are means, with standard deviations represented by vertical bars. (a) * The addition of MFGM resulted in a significant increase of anti-inflammatory IL-10 (P =
0·011). (b) * The addition of MFGM resulted in a significant decrease of sICAM concentration (P = 0·013). The sICAM graph and data exclude two subjects who were
deemed outliers with values more than three box lengths away from the 75th or 25th percentile.
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in MFGM attenuates the atherogenic milieu triggered by the
PO meal.
It is possible that the difference in sICAM between the PO
v. PO +MFGM treatments could stem from the difference in
the fatty acid composition. The PO+MFGM meal was higher
in short- and medium-chained SFA and lower in 18 : 2n-6 and
18 : 1n-9 compared with the PO meal. Chen et al.(48) showed
that when human retinal vascular endothelial cells were treated
with linoleic acid (18 : 2n-6) it resulted in increased ICAM
expression. The MFGM preparation used is composed of
complex lipids including sphingolipids, as well as bioactive
proteins, which may also play roles in the observed anti-
inflammatory effects(49).
When analysing the insulin iAUC over the 6 h postprandial
period, the total insulin concentration was significantly lower
in response to the PO+MFGM compared with the PO test
meal. To our knowledge there have not been any prior clinical
trials examining the effect of MFGM consumption on the
insulin response in human subjects. One study investigated
the postprandial effect of adding a dairy product rich in
sphingolipids, a lipid constituent of MFGM, to a high-fat
breakfast meal and found no significant difference in post-
prandial insulin concentrations(50). Branched-chain amino
acids may promote insulin secretion(51,52); thus the effect of
MFGM on insulin may be related to its amino acid
composition.
The secondary analysis based on baseline CRP concentra-
tions revealed that participants who were in an inflamed
state (CRP ≥ 3 mg/l) in the fasted condition had significantly
higher insulin concentrations after consuming the PO meal
compared with those who had normal baseline CRP concen-
trations. However, the addition of MFGM to the high-fat
test meal completely removed this difference. These results
suggest an interaction between diet and phenotype, whereby
consumption of MFGM by chronically inflamed individuals
normalised responses to a high-fat meal to closely resemble
that of a metabolically healthy profile.
Research has shown that cortisol peaks in the morning(53),
which was reflected in the present study, and decreases over
the course of the day. Elevated levels of cortisol inhibit the
Table 4. Concentrations of measured inflammatory markers at each time point
(Mean values and standard deviations)
Time point
0 h 1 h 3 h 6 h
Mean SD Mean SD Mean SD Mean SD Time × treatment: P
IL-10 (pg/ml)
PO meal 0·56 1·35 0·54 1·34 0·54 1·20 0·51 1·30 0·03
PO +MFGM meal 0·49 1·15 0·52 1·16 0·52 1·09 0·57 1·10
IL-6 (pg/ml)
PO meal 0·74 1·07 0·59* 0·86 0·61* 1·08 0·76†‡ 1·14 0·48
PO +MFGM meal 0·72 1·35 0·59 1·23 0·54 0·95 0·76 1·36
IL-8 (pg/ml)
PO 11·24 3·06 10·51* 3·30 9·63* 3·11 10·96 2·91 0·04
PO +MFGM 11·11 3·28 11·32 3·23 10·72 2·66 10·8 3·30
TNFα (pg/ml)
PO meal 2·49 0·70 2·36 0·56 2·29 0·62 2·36 0·64 0·13
PO +MFGM meal 2·34 0·66 2·36 0·64 2·27 0·61 2·22 0·66
IL-18 (pg/ml)
PO meal 145·48 91·64 148·44 75·95 162·38 109·73 150·95 73·05 0·59
PO +MFGM meal 154·25 83·16 152·19 73·41 155·38 78·06 160·03 72·09
MCP-1 (pg/ml)
PO meal 345·75 93·66 343·23 104·24 336·72 94·82 330·81 82·09 0·26
PO +MFGM meal 352·16 84·36 358·61 90·41 320·46 102·57 335·05 97·92
CRP (mg/l)
PO meal 4·42 4·69 4·39 4·23 4·42 4·43 4·64† 4·64 0·8
PO +MFGM meal 4·37 4·29 5·16 5·56 5·11 5·54 5·20 5·38
SAA (mg/l)
PO meal 3·93 3·48 4·04 3·58 3·81† 3·22 4·12‡ 3·71 0·91
PO +MFGM meal 11·85 30·79 12·76 32·76 12·20 31·68 12·82 33·37
sICAM-1 (mg/l)
PO meal 0·97 0·50 1·06* 0·53 1·00† 0·50 1·04*‡ 0·53 0·02
PO +MFGM meal 0·96 0·51 0·97 0·50 0·95 0·50 0·97 0·51
sVCAM-1 (mg/l)
PO meal 1·55 0·85 1·65* 0·86 1·58† 0·86 1·62‡ 0·86 0·13
PO +MFGM meal 1·49 0·83 1·51 0·84 1·46 0·82 1·52 0·85
Cortisol (μg/l)
PO meal 1139751 820859 967108 659595 703305*† 457081 653937*†‡ 577352 0·76
PO +MFGM meal 1083979 698219 933085 619060 780686 476281 613297 366507
PO, palm oil; PO +MFGM, palm oil + milk fat globule membrane; MCP-1, monocyte chemoattractant protein-1; CRP, C-reactive protein; SAA, serum amyloid A; sICAM, soluble
intracellular adhesion molecule; sVCAM, soluble vascular adhesion molecule.
* Significantly different from 0 h when both treatments analysed together (P < 0·05).
†Significantly different from 1 h when both treatments analysed together (P < 0·05).
‡Significantly different from 3 h when both treatments analysed together (P < 0·05).
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synthesis of pro-inflammatory cytokines(54). We hypothesised
that this potential inhibition may explain the observed initial
decrease in the pro-inflammatory cytokines (IL-6, IL-8,
TNFα) from baseline (blood draw schedule between 08·00
and 09·00 hours) to the 3 h blood draw (scheduled between
11·00 and 12·00 hours). However, none of the correlations
was significant.
In summary, the addition of a dairy fraction rich in MFGM
reduced the iAUC in postprandial insulin, total cholesterol,
LDL-cholesterol and sICAM responses over the 6 h postpran-
dial period, and increased the production of the anti-
inflammatory cytokine IL-10. The addition of a dairy fraction
rich in MFGM also attenuated the increases in insulin at 1 h in
individuals with elevated fasting CRP. Results from this study
suggest that the addition of a dairy fraction rich in MFGM
attenuates the negative metabolic and inflammatory effects
of a high-fat meal rich in saturated fat, specifically palmitate.
Supplementary material
The supplementary material for this article can be found at
http://www.journals.cambridge.org/10.1017/jns.2015.42
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